Trial reportFrontiers in neurology2026
Association between tirofiban administration and sex in outcomes following endovascular treatment for large vessel occlusion stroke.
Trial report in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intravenous tirofiban administered before endovascular treatment (EVT) did not improve 90-day outcomes compared to placebo in the RESCUE BT trial, and sex-specific heterogeneity remained uncertain. In this study, we aimed to evaluate the association between sex and tirofiban administration before EVT among patients enrolled in the RESCUE BT trial. Materials and methods: This Results: Of the 948 patients, 391 (41.2%) were women. The interaction between sex and treatment for a 90-day mRS score of 0-2 was not statistically significant ( Conclusion: In this exploratory analysis, no significant interaction between sex and treatment was identified, indicating that the association between tirofiban and 90-day outcomes did not differ by sex. Although women in the tirofiban arm had lower odds of achieving an mRS score of 0-2 at 90 days than men, this finding should be interpreted as hypothesis-generating and warrants further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.